Nanalysis Scientific Corp. (TSXV:NSCI)
Canada · Delayed Price · Currency is CAD | Market Cap | 16.03M -30.2% |
| Revenue (ttm) | 40.35M -6.2% |
| Net Income | -4.18M |
| EPS | -0.03 |
| Shares Out | 139.41M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 8,503 |
| Open | 0.1200 |
| Previous Close | 0.1250 |
| Day's Range | 0.1150 - 0.1200 |
| 52-Week Range | 0.1050 - 0.2050 |
| Beta | -0.00 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 24, 2026 |
About Nanalysis Scientific
Nanalysis Scientific Corp. develops, manufactures, and sells magnetic resonance technology products in Canada, the United States, Europe, Asia, and internationally. The company operates through the Scientific Equipment and Security Services segment. It offers nuclear magnetic resonance (NMR) spectrometers; magnetic resonance test, and measurement and diagnostic system; a 60-NMR platform; 100-NMR platform; 60-TEACH; QUAD NMR Console; and the Cameleon 4 console, a compact alternative to facilitate MRI for teaching. The company also provides softw... [Read more]
Financial Performance
In 2025, Nanalysis Scientific's revenue was 40.13 million, a decrease of -11.79% compared to the previous year's 45.50 million. Losses were -5.66 million, -58.44% less than in 2024.
Financial StatementsNews
Nanalysis Announces Management Changes
CALGARY, AB, Oct. 5, 2026 /PRNewswire/ -- Nanalysis Scientific Corp. (the "Company" or "Nanalysis") (TSXV: NSCI, FRA: 1N1) is pleased to announce the appointment of Philip Birkby as Interim Chief Fina...
Nanalysis Scientific Earnings Call Transcript: Q2 2026
Q2 2026 saw modest revenue growth and significant margin improvements, with adjusted EBITDA and net loss both showing strong year-over-year gains. Management expects a much stronger second half, driven by organic growth, new product launches, and improved cost structure.
Nanalysis Scientific Report: Q2 2026
Nanalysis Scientific published a report on August 24, 2026 containing material business information for investors and shareholders.
Nanalysis Scientific MD&A: Q2 2026
Nanalysis Scientific filed a regulatory document on August 24, 2026 disclosing important business information.
Nanalysis Scientific Earnings release: Q2 2026
Nanalysis Scientific released its Q2 2026 earnings on August 24, 2026, summarizing the period's financial results.
Nanalysis Announces Second Quarter 2026 Results
Reports $9.7 Million in Quarterly Revenue and $0.9 Million in Adjusted EBITDA CALGARY, AB, Aug. 24, 2026 /PRNewswire/ -- Nanalysis Scientific Corp. ("the Company", TSXV: NSCI, FRA: 1N1), a leader in p...
Nanalysis Announces Second Quarter 2026 Conference Call
Hosting Call at 10am ET on Monday, August 24th CALGARY, AB, Aug. 18, 2026 /PRNewswire/ -- Nanalysis Scientific Corp. ("the Company", TSXV: NSCI, FRA: 1N1), a leader in benchtop NMR instruments and ima...
Few Active Fixed Income ETFs Beat the Benchmark. These Do.
For decades, traditional index-based ETFs have served as the low-cost foundational anchor for core allocations, consistently demonstrating that outperforming a broad market index is an uphill battle.
Nanalysis Announces Grant of Options and Restricted Share Units
CALGARY, AB, July 3, 2026 /PRNewswire/ - Nanalysis Scientific Corp. (the "Company" or "Nanalysis") (TSXV: NSCI, FRA: 1N1) announces the Company's Board of Directors has granted 100,000 stock options (...
Nanalysis Provides Business Update Highlighting Quantum Technology Partnerships, $1Million in Non-Dilutive Non-Repayable Funding Award, Contract Wins and Corporate Activities
CALGARY, AB, June 23, 2026 Nanalysis Scientific Corp. ("the Company", TSXV: NSCI, FRA: 1N1), a leader in portable NMR spectrometers and imaging technology for industrial and research applications, ann...
Nanalysis Scientific Earnings Call Transcript: Q1 2026
Q1 2026 revenue grew 1% to CAD 10.67 million, with security services driving margin gains and net loss narrowing to CAD 1.28 million. Operational improvements and a successful equity raise strengthened financials, while new initiatives target future growth.
Nanalysis Scientific Report: Q1 2026
Nanalysis Scientific published a report on May 21, 2026 containing material business information for investors and shareholders.
Nanalysis Scientific MD&A: Q1 2026
Nanalysis Scientific filed a regulatory document on May 21, 2026 disclosing important business information.
Nanalysis Scientific Earnings release: Q1 2026
Nanalysis Scientific released its Q1 2026 earnings on May 21, 2026, summarizing the period's financial results.
Nanalysis Announces First Quarter 2026 Results
Reports Quarterly Revenue of $10.7 Million and Adjusted EBITDA of $292 Thousand CALGARY, AB, May 20, 2026 /PRNewswire/ - Nanalysis Scientific Corp. ("the Company", TSXV: NSCI, FRA: 1N1), a leader in p...
Nanalysis Announces First Quarter 2026 Conference Call
Hosting Call at 10am ET on Thursday, May 21st CALGARY, AB, May 13, 2026 /PRNewswire/ - Nanalysis Scientific Corp. ("the Company", TSXV: NSCI, FRA: 1N1), a leader in benchtop NMR instruments and imagin...
Nanalysis Announces Board Transition and Appointment of Three New Directors
CALGARY, AB, May 1, 2026 /PRNewswire/ - Nanalysis Scientific Corp. (the "Company", TSXV: NSCI, FRA: 1N1), a leader in portable NMR spectrometers and MRI technology for industrial and research applicat...
Nanalysis Scientific Earnings Call Transcript: Q4 2025
Q4 2025 revenue declined 13% year-over-year to CAD 10.7 million, mainly due to lower Scientific Equipment sales and the exit from third-party resale businesses. Gross margins and adjusted EBITDA also decreased, but operational improvements, new funding, and a focus on proprietary products position the company for improved profitability.
Nanalysis Scientific Earnings release: Q4 2025
Nanalysis Scientific released its Q4 2025 earnings on April 9, 2026, summarizing the period's financial results.
Nanalysis Scientific Report: Q4 2025
Nanalysis Scientific published a report on April 9, 2026 containing material business information for investors and shareholders.
Nanalysis Scientific MD&A: Q4 2025
Nanalysis Scientific filed a regulatory document on April 9, 2026 disclosing important business information.
Nanalysis Announces Fourth Quarter and Full Year 2025 Results
Reports Quarterly Revenue of $10.7 Million and Adjusted EBITDA of $1.2 Million Full Year Revenue of $40.1 Million and Adjusted EBITDA of $903 Thousand CALGARY, AB, April 8, 2026 /PRNewswire/ - Nanalys...
Nanalysis Announces Fourth Quarter and Full Year 2025 Conference Call
Hosting Call at 10am ET on Thursday, April 9th CALGARY, AB, April 2, 2026 /PRNewswire/ - Nanalysis Scientific Corp. ("the Company", TSXV: NSCI, FRA: 1N1), a leader in portable NMR instruments and imag...
Nanalysis Announces Closing of Second Tranche to Complete its $3.4 Million Offering
CALGARY, AB, Jan. 26, 2026 /PRNewswire/ - Nanalysis Scientific Corp. (the "Company" or "Nanalysis") ( TSXV: NSCI , OTCQX: NSCIF , FRA: 1N1) is pleased to announce, further to its December 8, 2025 and...
Nanalysis Announces Upsize to Private Placement and Closing of the First Tranche
CALGARY, AB , Dec. 23, 2025 /PRNewswire/ - Nanalysis Scientific Corp. (the "Company" or "Nanalysis") ( TSXV: NSCI , OTCQX: NSCIF , FRA: 1N1) is pleased to announce that it has closed the first tranch...